1
|
Wang Q, Zhuang L, Li P, Niu Q, Zhu P, He MX, Jiang H, Liu CC, Wang MJ, Chen L, Cheng H, Ma Y, Hu XX, Hu YP, Xu XP. Establishment of a novel human lymphoblastic cell strain with the long arm of chromosome 11 aberration without MLL rearrangement. Sci Rep 2017; 7:867. [PMID: 28408741 PMCID: PMC5429836 DOI: 10.1038/s41598-017-00874-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Accepted: 03/20/2017] [Indexed: 11/10/2022] Open
Abstract
At present, all cell strains derived from acute lymphoblastic leukemia (ALL) patients with the long arm of chromosome 11 aberration are accompanied with mixed lineage leukemia (MLL) gene rearrangement. In this study, we established a permanent ALL cell strain CHH-1 with the long arm of chromosome 11 aberration and without MLL rearrangement, hoping that it could be used for the research of ALL with such genetic abnormality. CHH-1 cell strain was certified through morphology, immunophenotype, genetics and immunoglobulin (Ig) gene rearrangement analysis. Cell characteristics including tumorigenic ability, semisolid colony forming ability, telomerase activity, autocrine and invasion were further detected. Cells were with an add(11)(q23) structural abnormality without MLL rearrangement, and were consistent with the genetic abnormality of the patient. In addition, these cells had features of tumor-forming ability, high colony forming capacity, unique cytokine autocrine mode, high telomerase activity, and high invasion ability. CHH-1 may prove to be a useful cell model for the research of human leukemia with genetic aberration in chromosome 11, and help explore the role of such genetic abnormality in the pathogenesis, progression and prognosis of ALL, and in developing new target drugs.
Collapse
Affiliation(s)
- Qian Wang
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China
| | - Lin Zhuang
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China
| | - Pei Li
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China
| | - Qiang Niu
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China
| | - Ping Zhu
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China
| | - Miao-Xia He
- Department of Pathology, ChangHai Hospital Affiliated of Second Military Medical University, No. 168 Changhai Road, Shanghai, 200433, P.R. China
| | - Hui Jiang
- Department of Pathology, ChangHai Hospital Affiliated of Second Military Medical University, No. 168 Changhai Road, Shanghai, 200433, P.R. China
| | - Chang-Cheng Liu
- Department of Cell Biology, Second Military Medical University, No. 800 Xiangyin Road, Shanghai, 200433, P.R. China
| | - Min-Jun Wang
- Department of Cell Biology, Second Military Medical University, No. 800 Xiangyin Road, Shanghai, 200433, P.R. China
| | - Li Chen
- Department of Hematology, ChangHai Hospital Affiliated of Second Military Medical University, No. 168 Changhai Road, Shanghai, 200433, P.R. China
| | - Hui Cheng
- Department of Hematology, ChangHai Hospital Affiliated of Second Military Medical University, No. 168 Changhai Road, Shanghai, 200433, P.R. China
| | - Yan Ma
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China
| | - Xiao-Xia Hu
- Department of Hematology, ChangHai Hospital Affiliated of Second Military Medical University, No. 168 Changhai Road, Shanghai, 200433, P.R. China
| | - Yi-Ping Hu
- Department of Cell Biology, Second Military Medical University, No. 800 Xiangyin Road, Shanghai, 200433, P.R. China.
| | - Xiao-Ping Xu
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China.
| |
Collapse
|
3
|
Abstract
In all organisms, cell proliferation is orchestrated by coordinated patterns of gene expression. Transcription results from the activity of the RNA polymerase machinery and depends on the ability of transcription activators and repressors to access chromatin at specific promoters. During the last decades, increasing evidence supports aberrant transcription regulation as contributing to the development of human cancers. In fact, transcription regulatory proteins are often identified in oncogenic chromosomal rearrangements and are overexpressed in a variety of malignancies. Most transcription regulators are large proteins, containing multiple structural and functional domains some with enzymatic activity. These activities modify the structure of the chromatin, occluding certain DNA regions and exposing others for interaction with the transcription machinery. Thus, chromatin modifiers represent an additional level of transcription regulation. In this review we focus on several families of transcription activators and repressors that catalyse histone post-translational modifications (acetylation, methylation, phosphorylation, ubiquitination and SUMOylation); and how these enzymatic activities might alter the correct cell proliferation program, leading to cancer.
Collapse
Affiliation(s)
- Helena Santos-Rosa
- The Wellcome Trust/Cancer Research UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, Cambridge, UK
| | | |
Collapse
|